Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

Open access
Lencioni, R., Kudo, M., Ye, S.‐L., Bronowicki, J.‐P., Chen, X.‐P., Dagher, L., Furuse, J., Geschwind, J. F., Guevara, L. Ladrón, Papandreou, C., Takayama, T., Yoon, S. K., Nakajima, K., Lehr, R., Heldner, S., Sanyal, A. J.·2014·International Journal of Clinical Practice

Abstract

BACKGROUND: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials. METHODS: Patients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician, were eligible for inclusion. Demographic data and disease/medical history were recorded at entry. Sorafenib dosing and adverse events (AEs) were collected at follow-up visits. The second interim analysis was undertaken when ~1500 treated patients were followed up for ≥ 4 months. RESULTS: Of the 1571 patients evaluable for safety, 61% had Child-Pugh A status and 23% Child-Pugh B. The majority of patients (74%) received the approved 800 mg initial sorafenib dose, regardless of Child-Pugh status; however, median duration of therapy was shorter in Child-Pugh B patients. The majority of drug-related AEs were grade 1 or 2, and the most commonly reported were consistent with previous reports. The incidence and nature of drug-related AEs were broadly similar across Child-Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population. CONCLUSIONS: Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in > 3000 patients are ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ijcp.12352

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 223

Metadata

Authors
Lencioni, R., Kudo, M., Ye, S. ‐., Bronowicki, J. ‐., Chen, X. ‐., Dagher, L., Furuse, J., Geschwind, J. F., Guevara, L. L., Papandreou, C., Takayama, T., Yoon, S. K., Nakajima, K., Lehr, R., Heldner, S., & Sanyal, A. J.
Venue
International Journal of Clinical Practice
Published
2013-11-28
Volume
68
Issue
5
Pages
609-617
ISSN
  • 1368-5031 (ISSN-L)
  • 1742-1241
OpenAlex
W2029029081
Cited by
223
References
2
FWCI
15.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. https://app.cochat.ai/papers/10.1111/ijcp.12352
The paper
Lencioni, R., Kudo, M., Ye, S. ‐., Bronowicki, J. ‐., Chen, X. ‐., Dagher, L., Furuse, J., Geschwind, J. F., Guevara, L. L., Papandreou, C., Takayama, T., Yoon, S. K., Nakajima, K., Lehr, R., Heldner, S., & Sanyal, A. J. (2014). GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. International Journal of Clinical Practice. https://doi.org/10.1111/ijcp.12352

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.